Our company
Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative immunomodulatory treatments for people living with rare immunological conditions.
Founded in 2007 and based in Lund, Sweden, Hansa is a biopharma company with a growing presence in Europe and the US. The company is listed on the Nasdaq Stockholm.
18
Years of innovation
11
Clinical and preclinical programs
+30
Nationalities represented in our workforce
Our vision
Through pioneering science and collaboration we enable life changing outcomes for patients with acute or serious immune mediated conditions.
Our mission
To successfully develop and commercialize novel immunomodulatory therapies by leveraging our expertise in enzyme technology and immunology to transform care for patients with acute or complex immune disorders.
Our values
Courage
We do not shy way from challenges as we are driven by patient needs. We stand up for what we believe in but are respectful of alternative views and adapt to new information. We dare to be authentic, transparent, science led and realistic.
Accountability
We have the courage to act decisively and take ownership of our actions and outcomes. We follow through on our commitments and hold ourselves and each other to high standards.
Integrity
We act and communicate with honesty, respect, transparency, and accountability. We hold ourselves to the highest ethical standards and earn trust through consistent, thoughtful and principled action.
Pioneering
We challenge the status quo and stay focused across uncharted waters, driven by our patient-centric focus. We adapt quickly to change, while remaining solution-oriented and committed to our mission. We deliver both innovation and value efficiently and sustainably.
Our technology platform
Hansa has developed a proprietary antibody-cleaving enzyme technology platform to target pathogenic or disease-causing IgG antibodies.
Imlifidase is a first-generation enzyme designed to rapidly and specifically inactivate IgG antibodies in plasma and tissues through a single intravenous treatment.
HNSA-5487 is a next-generation enzyme that could potentially expand the IgG-free window through short-term repeat dosing.
We are currently evaluating our enzymes across a wide spectrum of disease areas and indications in an effort to address significant unmet medical needs.
Our approach to sustainability
Sustainability is considered an important part of Hansa’s business. We are committed to advancing science in areas of high unmet need and ensuring access to new medicines for patients and clinicians. We take an agile approach to Sustainability – evolving the strategy and priority areas of focus over time and in line with the Company’s growth.
Our ability to advance science and deliver innovative new medicines is grounded in a culture that values authentic, transparent communication and encourages an inclusive and diverse workplace. Being authentic and feeling empowered to speak up remains a top priority for the Company.
Diversity and inclusion
Our values
At Hansa Biopharma, we strive to create an inclusive environment that embraces difference and fosters inclusion. We believe that valuing diversity and inclusion will create an environment in which all talent can grow and our employees can thrive, and we are fully committed to ensuring our employees are treated equally, regardless of their ethnicity, sex, religion, disability, age, sexual orientation, gender identity or expression.
Equality and diversity at Hansa
We value and promote equality and inclusion in our workforce and across our global leadership. To ensure our board is inclusive, we have implemented a board diversity policy, which outlines a required blend of geographical and cultural backgrounds, professional experiences, and knowledge, including gender balance.
To specifically ensure gender equality at Hansa, we conduct yearly salary surveys to ensure that men and women receive equal pay for equivalent work.